ctdna
No description yet: the sentence for this tag has not been written. 7 records carry it: 5 people, 1 roadmap, 1 biomarker.
Related tags
By kind
7 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alberto Bardelli Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin · Istituto di Candiolo IRCCS (FPO) Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade. | Colorectal cancer | none | colorectal, resistance | ||
ctDNA MRD positivity (molecular residual disease after curative treatment) Genome-wide readout A ctDNA MRD test looks for the tumour's own mutations in blood after surgery. Detection predicts relapse months before scans, and in 2026 the FDA approved Signatera as the companion test selecting bladder cancer patients for adjuvant atezolizumab. | Bladder & urothelial cancer, Colorectal cancer, Triple-negative breast cancer | none | biomarker, genome-wide | ||
ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment Blood carries fragments of tumour DNA. This roadmap follows the tests that read them, from the first sighting in 1948 to blood tests that now choose a drug, spare chemotherapy, or screen for many cancers at once, and it lists the readouts to watch next. | none | none | liquid-biopsy, mrd, mced | ||
Jeanne Tie Medical Oncologist, Peter MacCallum Cancer Centre; Laboratory Head, Walter and Eliza Hall Institute · Walter and Eliza Hall Institute of Medical Research Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery. | Colorectal cancer | none | colorectal, de-escalation | ||
Nitzan Rosenfeld Professor of Cancer Genomics, Barts Cancer Institute; former Senior Group Leader, CRUK Cambridge Institute · Barts Cancer Institute / Barts Health NHS Trust Showed that whole-exome sequencing of blood can track how a cancer evolves, and co-founded Inivata. | none | none | liquid-biopsy, genomics | ||
Thomas Powles Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London · Barts Cancer Institute / Barts Health NHS Trust Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care. | Bladder & urothelial cancer, Renal cell carcinoma | none | urothelial, adc, trialist | ||
Viktor A. Adalsteinsson Director, Gerstner Center for Cancer Diagnostics, Broad Institute of MIT and Harvard · Broad Institute of MIT and Harvard Engineer who showed low-pass sequencing of blood can replace tumour biopsies and built ultra-sensitive MRD tests. | none | none | mrd, diagnostics |
